Are the Broad Institute’s CRISPR patents too broad?

The ability of the CRISPR/Cas9 system to make precisely targeted mutations in genes, including human genes, has taken the biotech industry by storm. It has been described by some as being the most important development in biology since the discovery of the structure of DNA by Watson and Crick in 1953.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Europe

IP in the deal room: The risks that bite before, during and after closing

7 May 2026 Experts from Johnson & Johnson and Novartis took the stage at INTA to share the pitfalls lurking inside mergers, acquisitions and spin-offs and what in-house counsel can do about them.

Europe

Five generations at work: How teams are bridging the gap

6 May 2026 Panellists at INTA share how workplaces can bridge generational divides and why those differences may be a team’s biggest strengths.

Europe

WATCH: John Ward, trademarks VP and associate GC of Moderna, at INTA

5 May 2026 John Ward, vice president and associate general counsel of trademarks at Moderna, chats with Tom Phillips at INTA 2026.